H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Vericel (VCEL – Research Report) today and set a price target of $22.00. The company’s shares closed last Wednesday at $15.92.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.9% and a 36.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vericel with a $25.00 average price target, which is a 47.1% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $21.00 price target.
The company has a one-year high of $19.57 and a one-year low of $6.78. Currently, Vericel has an average volume of 611.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.